Fogarty Innovation (formerly Fogarty Institute) is a non-profit MedTech incubator that mentors early-stage device founders through technology development, regulatory strategy, and clinical trial planning, with strong ties to Stanford and El Camino Hospital. Fogarty Innovation is a nonprofit device incubator in Mountain View, California, founded by surgeon and inventor Thomas Fogarty. It supports companies with lab space, mentorship and support through early clinical work. It focuses on device development and education.

Why it matters

Reflects Dr. Fogarty's tradition of physician-led device innovation. Programs span structural heart, neurovascular, and surgical specialties.

Common pitfalls

•Confusing Fogarty Innovation's guidance with official regulatory agency directives is a common mistake.
•Assuming their programs guarantee regulatory clearance or approval will lead to unmet expectations.
•Failing to conduct independent due diligence on regulatory pathways, despite their mentorship, can result in significant delays.
•Overlooking the importance of quality management system implementation from the earliest stages of device development is a frequent pitfall.
•Relying solely on their clinical trial planning without deep understanding of relevant regulatory requirements for human subject protection is a risk.

Sources

Fogarty Innovation · Fogarty
RAPS · RAPS
AAMI · AAMI

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.